99 related articles for article (PubMed ID: 27449101)
21. miRNA-770-5p expression is upregulated in patients with type 2 diabetes and miRNA-770-5p knockdown protects pancreatic β-cell function via targeting BAG5 expression.
Wang M; Wei J; Ji T; Zang K
Exp Ther Med; 2021 Jul; 22(1):664. PubMed ID: 33986829
[TBL] [Abstract][Full Text] [Related]
22. miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer.
Yu X; Zhang X; Wang G; Wang B; Ding Y; Zhao J; Liu H; Cui S
Cancer Cell Int; 2020 Nov; 20(1):534. PubMed ID: 33292230
[TBL] [Abstract][Full Text] [Related]
23. Circular RNA circ_ASAP2 promotes cell viability, migration, and invasion of gastric cancer cells by regulating the miR-770-5p/CDK6 axis.
Chen B; Ji F; Wen X; Jin Z
Int J Clin Exp Pathol; 2020; 13(11):2806-2819. PubMed ID: 33284890
[TBL] [Abstract][Full Text] [Related]
24. [MiR-433 reverses chemoresistance to docetaxel by targeting Notch1 in breast cancer cells].
Hu X; Huang P; Wang J; He W; Zhao P; Yao G; Ye C
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(7):888-894. PubMed ID: 33168512
[TBL] [Abstract][Full Text] [Related]
25. Integrated Analysis of Hub Genes and miRNAs in Dilated Cardiomyopathy.
Huang K; Wen S; Huang J; Wang F; Pang L; Wang Y; Sun X
Biomed Res Int; 2020; 2020():8925420. PubMed ID: 33015184
[TBL] [Abstract][Full Text] [Related]
26. NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis.
Zhu M; Yang L; Wang X
Cancer Manag Res; 2020; 12():7277-7289. PubMed ID: 32884343
[TBL] [Abstract][Full Text] [Related]
27. miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1.
Zhang D; Li Y; Sun P
Exp Ther Med; 2020 Jan; 19(1):339-346. PubMed ID: 31853309
[TBL] [Abstract][Full Text] [Related]
28. Analysis of microarray data for identification of key microRNA signatures in glioblastoma multiforme.
Shaji SK; Sunilkumar D; Mahalakshmi NV; Kumar GB; Nair BG
Oncol Lett; 2019 Aug; 18(2):1938-1948. PubMed ID: 31423264
[TBL] [Abstract][Full Text] [Related]
29. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Noyan S; Gurdal H; Gur Dedeoglu B
PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
[TBL] [Abstract][Full Text] [Related]
30. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells.
Xie X; Huang N; Zhang Y; Wei X; Gao M; Li M; Ning J; Liu W; Zhao Q; Wang H; Gu K
J Cancer; 2019; 10(4):1039-1051. PubMed ID: 30854110
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-770 affects proliferation and cell cycle transition by directly targeting CDK8 in glioma.
Zhang JF; Zhang JS; Zhao ZH; Yang PB; Ji SF; Li N; Shi QD; Tan J; Xu X; Xu CB; Zhao LY
Cancer Cell Int; 2018; 18():195. PubMed ID: 30524203
[TBL] [Abstract][Full Text] [Related]
32. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.
Zhang C; Chen B; Jiao A; Li F; Sun N; Zhang G; Zhang J
BMC Cancer; 2018 Nov; 18(1):1179. PubMed ID: 30486878
[TBL] [Abstract][Full Text] [Related]
33. The Network of Non-coding RNAs in Cancer Drug Resistance.
Corrà F; Agnoletto C; Minotti L; Baldassari F; Volinia S
Front Oncol; 2018; 8():327. PubMed ID: 30211115
[TBL] [Abstract][Full Text] [Related]
34. Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.
Biersack B
Noncoding RNA Res; 2017 Mar; 2(1):1-17. PubMed ID: 30159416
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA‑665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10.
Liu J; Jiang Y; Wan Y; Zhou S; Thapa S; Cheng W
Mol Med Rep; 2018 Sep; 18(3):2661-2668. PubMed ID: 30015865
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.
Kashyap D; Tuli HS; Garg VK; Goel N; Bishayee A
Mol Diagn Ther; 2018 Apr; 22(2):179-201. PubMed ID: 29388067
[TBL] [Abstract][Full Text] [Related]
37. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.
Liu X; Zhang Z; Deng C; Tian Y; Ma X
Oncotarget; 2017 Sep; 8(37):62769-62779. PubMed ID: 28977987
[TBL] [Abstract][Full Text] [Related]
39. The molecular mechanisms of chemoresistance in cancers.
Zheng HC
Oncotarget; 2017 Aug; 8(35):59950-59964. PubMed ID: 28938696
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation.
Chen LG; Xia YJ; Cui Y
Oncol Rep; 2017 Jul; 38(1):100-108. PubMed ID: 28560419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
